comprehensive -WSS

comprehensive

author：fashion 2025-09-30 17:59:45 - browse：8

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： White House calls on federal agencies to crack down on AI abuses

hotspot

WSS

David Sabatini, ex

World's first CRISPR

Medicare solvency divides Republicans at the presidential debate

STAT Executive Editor Rick Berke on STAT's 8th birthday

In key trial, Verve's treatment lowers cholesterol levels in patients

FDA approves Recor Medical high blood pressure device

Wikipedia

comprehensive

hotspot

In age of alternative facts, a scholarly course on calling out crap

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

At least 13 dead in Texas as scorching temps continue

Does good food count as health care? Study aims to find out

Peter Hotez and the public health issue of online harassment

The Sacklers, horror, and ‘The Fall of the House of Usher’

In age of alternative facts, a scholarly course on calling out crap

More doctors should go into startup world

Continuity nursing helped my family in our darkest PICU moments

Does good food count as health care? Study aims to find out

Wikipedia

Just how powerful is the placebo effect?

10 million people disenrolled from Medicaid over past six months

PBM reforms clear House panel

Why medical students are struggling with mental health

Will General Catalyst be the first of many hospital takeovers?

Congress must reauthorize a committee to support older Americans

hotspot

explore

entertainment

leisure time